{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:01:04Z","timestamp":1794654064782,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010932","name":"Louisiana State University Shreveport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010932","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.04.102","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T22:00:46Z","timestamp":1652479246000},"page":"3638-3646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments"],"prefix":"10.1016","volume":"40","author":[{"given":"Fengsheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn","family":"Heidecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8577-4790","authenticated-orcid":false,"given":"Jennifer","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-1117","authenticated-orcid":false,"given":"Eberhard","family":"Durr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 1","key":"10.1016\/j.vaccine.2022.04.102_b0005","first-page":"3","article-title":"Why and how epstein-barr virus was discovered 50 years ago","volume":"390","author":"Epstein","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7335","key":"10.1016\/j.vaccine.2022.04.102_b0010","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from burkitt's lymphoma","volume":"283","author":"Epstein","year":"1964","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.102_b0015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1186\/s12879-019-4578-y","article-title":"Predictors of epstein-barr virus serostatus in young people in england","volume":"19","author":"Winter","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.102_b0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.102_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"issue":"5974","key":"10.1016\/j.vaccine.2022.04.102_b0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/310207a0","article-title":"DNA sequence and expression of the B95\u20138 Epstein-Barr virus genome","volume":"310","author":"Baer","year":"1984","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.vaccine.2022.04.102_b0035","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJM197606172942501","article-title":"Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx","volume":"294","author":"Niederman","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.102_b0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.102_b0045","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ijc.27858","article-title":"EBV primary infection in childhood and its relation to B-cell lymphoma development: a mini-review from a developing region","volume":"133","author":"Chabay","year":"2013","journal-title":"Int J Cancer"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2022.04.102_b0050","first-page":"211","article-title":"Infectious mononucleosis","volume":"390","author":"Dunmire","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2022.04.102_b0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2018.00211","article-title":"Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update","volume":"8","author":"Smatti","year":"2018","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.102_b0060","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1038\/cti.2015.1","article-title":"Infectious mononucleosis","volume":"4","author":"Balfour","year":"2015","journal-title":"Clin Transl Immunology"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.102_b0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","article-title":"EBV persistence in memory B cells in vivo","volume":"9","author":"Babcock","year":"1998","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.102_b0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/1348-0421.12155","article-title":"Regulation of Epstein-Barr virus reactivation from latency","volume":"58","author":"Murata","year":"2014","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2022.04.102_b0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/978-981-10-7230-7_21","article-title":"EBV in T-\/NK-cell tumorigenesis","volume":"1045","author":"Kimura","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.102_b0080","doi-asserted-by":"crossref","first-page":"e1004309","DOI":"10.1371\/journal.ppat.1004309","article-title":"Assembly and architecture of the EBV B cell entry triggering complex","volume":"10","author":"Sathiyamoorthy","year":"2014","journal-title":"PLoS Pathog"},{"issue":"20","key":"10.1016\/j.vaccine.2022.04.102_b0085","doi-asserted-by":"crossref","first-page":"11686","DOI":"10.1128\/JVI.01349-14","article-title":"The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion","volume":"88","author":"Chen","year":"2014","journal-title":"J Virol"},{"issue":"48","key":"10.1016\/j.vaccine.2022.04.102_b0090","doi-asserted-by":"crossref","first-page":"20464","DOI":"10.1073\/pnas.0907508106","article-title":"Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8","volume":"106","author":"Chesnokova","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.102_b0095","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus","volume":"3","author":"Chen","year":"2018","journal-title":"Nat Microbiol"},{"issue":"21","key":"10.1016\/j.vaccine.2022.04.102_b0100","doi-asserted-by":"crossref","first-page":"12193","DOI":"10.1128\/JVI.01597-14","article-title":"Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB","volume":"88","author":"Chesnokova","year":"2014","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2022.04.102_b0105","doi-asserted-by":"crossref","first-page":"15036","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.vaccine.2022.04.102_b0110","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/jnci\/92.22.1849","article-title":"Infection of breast epithelial cells with Epstein-Barr virus via cell-to-cell contact","volume":"92","author":"Speck","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1016\/j.vaccine.2022.04.102_b0115","doi-asserted-by":"crossref","first-page":"12613","DOI":"10.1128\/JVI.78.22.12613-12624.2004","article-title":"Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers","volume":"78","author":"Pegtel","year":"2004","journal-title":"J Virol"},{"issue":"46","key":"10.1016\/j.vaccine.2022.04.102_b0120","doi-asserted-by":"crossref","first-page":"16544","DOI":"10.1073\/pnas.1400818111","article-title":"Efficient replication of Epstein-Barr virus in stratified epithelium in vitro","volume":"111","author":"Temple","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.102_b0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-16","article-title":"The long and complicated relationship between epstein-barr virus and Epithelial Cells","volume":"91","author":"Hutt-Fletcher","year":"2017","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.102_b0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2012.02.004","article-title":"The biology of EBV infection in human epithelial cells","volume":"22","author":"Tsao","year":"2012","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.102_b0135","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/cr.2015.50","article-title":"In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures","volume":"25","author":"Ni","year":"2015","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.102_b0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/infdis\/125.4.403","article-title":"Infectious mononucleosis: appearance of neutralizing antibody to Epstein-Barr virus measured by inhibition of formation of lymphoblastoid cell lines","volume":"125","author":"Miller","year":"1972","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.102_b0145","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/jvi.15.5.1065-1072.1975","article-title":"Assay for Epstein-Barr virus based on stimulation of DNA synthesis in mixed leukocytes from human umbilical cord blood","volume":"15","author":"Robinson","year":"1975","journal-title":"J Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2022.04.102_b0150","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1073\/pnas.95.14.8245","article-title":"Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells","volume":"95","author":"Delecluse","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.102_b0155","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s007050050574","article-title":"Epstein-Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry","volume":"144","author":"Speck","year":"1999","journal-title":"Arch Virol"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.102_b0160","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/JVI.78.13.7004-7015.2004","article-title":"Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system","volume":"78","author":"Kanda","year":"2004","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.102_b0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"issue":"6367","key":"10.1016\/j.vaccine.2022.04.102_b0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/356347a0","article-title":"Epstein-Barr virus infection and replication in a human epithelial cell system","volume":"356","author":"Li","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.04.102_b0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jviromet.2017.04.012","article-title":"Development of a robust, higher throughput green fluorescent protein (GFP)-based Epstein-Barr Virus (EBV) micro-neutralization assay","volume":"247","author":"Lin","year":"2017","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.102_b0180","doi-asserted-by":"crossref","first-page":"e2020016","DOI":"10.4084\/mjhid.2020.016","article-title":"Development of an improved Epstein-Barr Virus (EBV) neutralizing antibody assay to facilitate development of a prophylactic gp350-subunit EBV vaccine","volume":"12","author":"Liu","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.102_b0185","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.102_b0190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/vaccines8020169","article-title":"A pentavalent Epstein-Barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr virus infection in immunized rabbits","volume":"8","author":"Escalante","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.102_b0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/vaccines9030285","article-title":"Immunization with Epstein-Barr Virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge","volume":"9","author":"Cui","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.102_b0200","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1128\/jvi.68.9.6069-6073.1994","article-title":"Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV","volume":"68","author":"Shimizu","year":"1994","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.102_b0205","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.4049\/jimmunol.144.12.4788","article-title":"Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata","volume":"144","author":"Daibata","year":"1990","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.102_b0210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1097-2765(02)00465-3","article-title":"Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1","volume":"9","author":"Mullen","year":"2002","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.102_b0215","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1128\/jvi.66.8.4972-4981.1992","article-title":"Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants","volume":"66","author":"Marchini","year":"1992","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2022.04.102_b0220","doi-asserted-by":"crossref","first-page":"10142","DOI":"10.1128\/JVI.74.21.10142-10152.2000","article-title":"Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350\/220) demonstrates the existence of additional viral ligands","volume":"74","author":"Janz","year":"2000","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.102_b0225","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1128\/JVI.73.3.2115-2125.1999","article-title":"CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus","volume":"73","author":"Fingeroth","year":"1999","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.102_b0230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/viro.2001.1072","article-title":"Growth transformation of primary epithelial cells with a NPC-derived Epstein-Barr virus strain","volume":"288","author":"Danve","year":"2001","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.102_b0235","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1084\/jem.176.5.1405","article-title":"Characterization of an Epstein-Barr virus receptor on human epithelial cells","volume":"176","author":"Birkenbach","year":"1992","journal-title":"J Exp Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:07Z","timestamp":1759403707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":47,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005692"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.102","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}